U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Substance Class Mixture
Created
by admin
on Sat Dec 16 01:50:36 GMT 2023
Edited
by admin
on Sat Dec 16 01:50:36 GMT 2023
Record UNII
6D53G0FD0Z
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Alternative Definition
Name Type Language
PLASMA PROTEIN FRACTION (HUMAN)
WHO-DD  
Common Name English
PLASMA PROTEIN FRACTION HUMAN
Common Name English
Plasma protein fraction (human) [WHO-DD]
Common Name English
PLASMA PROTEIN FRACTION,HUMAN [VANDF]
Common Name English
PLASMA, PROTEIN
Common Name English
PLASMA, PROTEIN FRACTION (HUMAN)
Common Name English
PLASMA PROTEIN
Common Name English
Classification Tree Code System Code
CFR 21 CFR 640.93
Created by admin on Sat Dec 16 01:51:25 GMT 2023 , Edited by admin on Sat Dec 16 01:51:25 GMT 2023
CFR 21 CFR 640.92
Created by admin on Sat Dec 16 01:51:25 GMT 2023 , Edited by admin on Sat Dec 16 01:51:25 GMT 2023
CFR 21 CFR 640.91
Created by admin on Sat Dec 16 01:51:25 GMT 2023 , Edited by admin on Sat Dec 16 01:51:25 GMT 2023
CFR 21 CFR 640.90
Created by admin on Sat Dec 16 01:51:25 GMT 2023 , Edited by admin on Sat Dec 16 01:51:25 GMT 2023
CFR 21 CFR 640.94
Created by admin on Sat Dec 16 01:51:25 GMT 2023 , Edited by admin on Sat Dec 16 01:51:25 GMT 2023
Code System Code Type Description
FDA UNII
6D53G0FD0Z
Created by admin on Sat Dec 16 01:51:25 GMT 2023 , Edited by admin on Sat Dec 16 01:51:25 GMT 2023
PRIMARY
DRUG BANK
DB13968
Created by admin on Sat Dec 16 01:51:25 GMT 2023 , Edited by admin on Sat Dec 16 01:51:25 GMT 2023
PRIMARY
RXCUI
33835
Created by admin on Sat Dec 16 01:51:25 GMT 2023 , Edited by admin on Sat Dec 16 01:51:25 GMT 2023
PRIMARY RxNorm
DAILYMED
6D53G0FD0Z
Created by admin on Sat Dec 16 01:51:25 GMT 2023 , Edited by admin on Sat Dec 16 01:51:25 GMT 2023
PRIMARY
EVMPD
SUB127871
Created by admin on Sat Dec 16 01:51:25 GMT 2023 , Edited by admin on Sat Dec 16 01:51:25 GMT 2023
PRIMARY
All of the following components must be present:
Unknown Structure
UNSPECIFIED SUBSTANCE
(not present in database)
Related Record Type Details
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
GLE is approximately 97.5% bound to human plasma proteins independent of concentration from 0.1 to 30 μM (800 to 25,200 ng/mL).
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
Plasma protein binding for valdecoxib is about 98% over the concentration range (21-2384 ng/mL).
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
Plasma protein binding of relugolix is 68 to 71%, primarily to albumin and to a lesser extent to α1-acid glycoprotein.
LIGAND->BINDER
BINDING
LIGAND->BINDER
Primarily to albumin
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
with no concentration dependence over the range of 100–500 ng/mL
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
In vitro, human plasma protein binding was determined to be low (<18%) across a range of peramivir concentrations (10-1000 ng/mL) with no partitioning into red blood cells (Study DM99362).
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
The high affinity binding protein for amprenavir is alpha1-acid glycoprotein (AAG).
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
Protein binding of tepotinib is 98% and is independent of drug concentration at clinically relevant exposures.
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
In vitro plasma protein binding of lonafarnib was greater than or equal to 99% over the concentration range between 0.5 to 40.0 μg/mL.
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
Ivacaftor is approximately 99% bound to plasma proteins, primarily to albumin, and also to alpha 1-acid glycoprotein and human gamma-globulin.
BINDING
LIGAND->BINDER
Glasdegib is 91% bound to human plasma proteins in vitro
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
Percent binding
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
The percentages ixabepilone bound to proteins at concentrations of 50, 500 and 5000 ng/mL were 76.6%, 72.0% and 67.1%, respectively. The protein binding of ixabepilone was not concentration dependent from 50 ng/mL to 5000 ng/mL.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
primarily to alpha-1-acid glycoprotein.
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
In vitro protein binding in human serum was 99.5% to 90.9% over an ibandronate concentration range of 2 to 10 ng/mL in one study and approximately 85.7% over a concentration range of 0.5 to 10 ng/mL in another study.
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
Human plasma protein binding of pretomanid is approximately 86.4% and is independent of drug concentration.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
Plasma protein binding is estimated to be 85 to 90% in the concentration range 1 to 230 nmol/L, independent of gender.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
in vivo
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
tezacaftor are approximately 99% bound to plasma proteins, primarily to albumin.
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
Plasma protein binding is independent on nelarabine concentrations.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
The bound concentration increased slightly (,2%) as the concentration of 14C-rifapentine increased from 0.5 to 10 mg/ml. At concentrations above 10 mg/ml, protein binding did not appear to vary with increasing concentration.
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
For M16, protein binding was moderate and ranged from 82.6 to 85.7% 0.5 hr after avanafil administration.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
Plasma protein binding was greater than 99% and is independent of plasma concentrations.
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
Reported not to bind to serum proteins
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDER->LIGAND
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LDV is >99.8% bound to human plasma proteins when determined in vitro with equilibrium dialysis. In agreement with in vitro data, LDV protein binding was ≥ 98% in healthy subjects and in subjects with renal or hepatic impairment.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
Encorafenib is 86% bound to human plasma proteins and binding is not concentrationdependent
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
Unable to clear indoxyl sulfate in hemodialysis.
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
Abametapir plasm protein binding ranged from 91.3 – 92.3% and was concentration independent within the tested concentration range of 50 – 800 ng/mL.
BINDING
LIGAND->BINDER
LIGAND->BINDER
Miglustat does not bind to plasma proteins.
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
Binding to human plasma proteins was low (approximately 22 %) and independent of the concentration of zoledronic acid.
BINDING
LIGAND->BINDER
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9-15 mg/ml).
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
Protein binding of lemborexant is approximately 93.2% to 94.0% between 29 ng/mL and 71 ng/mL.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
The protein binding of either piperacillin or tazobactam is unaffected by the presence of the other compound.
BINDING
LIGAND->BINDER
LIGAND->BINDER
Viloxazine is 76-82% bound to human plasma proteins over the blood concentration range of 0.5 mcg/mL to 10 mcg/mL.
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
The in vitro protein binding in human plasma is below 8% for tipiracil.
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
~90% Gilteritinib bound to plasma proteins, mainly albumin
BINDING
LIGAND->BINDER
LIGAND->BINDER
SUB_CONCEPT->SUBSTANCE
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
independent of concentration
BINDING
BINDER->LIGAND
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
In vitro, protein binding of lorlatinib to human plasma proteins, including serum albumin and α1-acid glycoprotein, was 66% at a concentration of 2.4 μM.
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
The human plasma protein binding of lasmiditan is approximately 55% to 60% and independent of concentration between 15 and 500 ng/mL.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
Plasma protein binding of alvimopan was independent of concentration over ranges observed clinically and averaged 80% .
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
Plasma protein binding is 25% to 30% in the concentration range from 37 to 1850 ng/mL.
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
Protein binding of selpercatinib is 97% in vitro and is independent of concentration.
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
In vitro binding of gefitinib to human plasma proteins (serum albumin and α1-acid glycoprotein) is 90% and is independent of drug concentrations.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
Protein binding of tivozanib is ≥ 99%, primarily to albumin in vitro and is independent of concentration.
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDER->LIGAND
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
The protein binding of M1 is ~97% and is concentration independent.
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
The plasma protein binding of milnacipran is approximately 13% and is independent of the concentration (Study# M013).
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
The protein binding is concentration dependent and decreases with increasing telaprevir concentrations at all concentrations of human serum albumin (HSA) and α-1-acid glycoprotein (AAG). In addition, protein binding of telaprevir is affected by the concentration of HSA and AAG.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
Cenobamate mainly binds with human albumin protein and not with α1-acid glycoprotein.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
IN VITRO
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
The in vitro plasma protein binding of tigecycline ranges from approximately 71% to 89% at concentrations observed in clinical studies (0.1 to 1.0 μg/mL).
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
Protein binding (primarily to serum albumin) of vericiguat is about 98%.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
In human plasma, the binding of R093877 increased at higher pH values. In the pH-range 7.1 to 7.7, the percentage bound increased from 23.3% to 35.5%
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
PARENT -> BIOSIMILAR
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
independent of concentration
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
decreases as concentration increases
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
In vitro, tazemetostat is 87.7 to 91.1% bound to human plasma proteins over the concentration range of 1 to 30 M.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
In vitro, protein binding of talazoparib is 74% and is independent of talazoparib concentration.
BINDING
LIGAND->BINDER
LIGAND->BINDER
Binding to the latter protein is saturable, and the drug displays nonlinear kinetics with respect to plasma concentration and clearance.
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
The binding of Relebactam to human plasma proteins is approxi mately22% and is independent ofconcentration at a range of 5 to 50 μM.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
The plasma protein to whichSN-38 predominantly binds is albumin.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
In vitro, neratinib was highly bound (N 99 %) to human plasma proteins at clinical exposures. click to edit
BINDING
LIGAND->BINDER
The mean plasma protein binding of vildagliptin in humans was low (9.3%) and also independent of concentration.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
Total in vitro protein binding is approximately 60% to 70% and is primarily due to human serum albumin. Protein binding is not modified in elderly subjects and in patients with hepatic impairment.
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
Zanubrutinib is approximately 94.2% bound to human plasma proteins in vitro, independent of concentration.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
independent of capmatinib concentration
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER